Lumida
/MEDP
⌘K
Medpace Holdings Inc

Medpace Holdings Inc

MEDP
$587.52USD+0.75%+4.36 today

MARKET CAP

16.4B

P/E (TTM)

37.0x

FWD P/E

DAY RANGE

$585 – $595

52W RANGE

$373
$678

AI Summary

Stalk
StalkMedium

MEDP is exhibiting signs of a mean-reversion bounce as it tests the rising 200-day SMA near oversold conditions. The Bearish Exhaustion pattern indicates sellers are losing control, suggesting a potential medium-term bottom. Short-term, price remains below the 9- and 20-EMAs, warranting patience for a cleaner pullback entry. Overall, structural context supports deferred bullish engagement on pullbacks into the $570–$580 support zone.

  • Q4 2025 revenue $708.5 M, +32% YoY
  • Q4 net new awards +39.1% YoY; book-to-bill ratio 1.04
  • Q4 cancellations remained high; net book-to-bill at 1.04 risks momentum
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.1B$1.5B$1.9B$2.1B$2.5B
YoY %+23.4%+27.8%+29.2%+11.8%+20.0%
P / Sales7.2x4.8x5.2x5.0x6.6x
EV / Sales7.4x5.4x5.6x5.3x7.0x
Gross Profit, Adj.$1.1B$1.5B$524.5M$656.3M$760.6M
YoY %+23.4%+27.8%-64.1%+25.1%+15.9%
Margin %100.0%100.0%27.8%31.1%30.1%
EV / Gross Profit7.4x5.4x20.2x17.1x23.1x
EBITDA, Adj.$219.7M$301.0M$363.2M$476.1M$563.1M
YoY %+17.8%+37.0%+20.6%+31.1%+18.3%
Margin %19.2%20.6%19.3%22.6%22.3%
EV / EBITDA38.5x26.4x29.1x23.6x31.3x
EBIT$198.6M$278.7M$336.8M$446.9M$534.9M
YoY %+18.9%+40.3%+20.9%+32.7%+19.7%
Margin %17.4%19.1%17.9%21.2%21.1%
EV / EBIT42.5x28.5x31.4x25.2x32.9x
Net Income$181.8M$245.4M$282.8M$404.4M$451.1M
YoY %+25.5%+34.9%+15.3%+43.0%+11.6%
Net Margin15.9%16.8%15.0%19.2%17.8%
EPS (GAAP)$4.81$7.28$8.88$12.63$15.28
YoY %+25.3%+51.4%+22.0%+42.2%+21.0%